Anti-CRTC1/ TORC1/ MAML2 monoclonal antibody
Anti-CRTC1/ TORC1/ MAML2 antibody for FACS & in-vivo assay
Go to TORC1/CRTC1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T20017-Ab-1/ GM-Tg-hg-T20017-Ab-2 | Anti-Human TORC1/CRTC1 monoclonal antibody | Human |
GM-Tg-rg-T20017-Ab-1/ GM-Tg-rg-T20017-Ab-2 | Anti-Rat TORC1/CRTC1 monoclonal antibody | Rat |
GM-Tg-mg-T20017-Ab-1/ GM-Tg-mg-T20017-Ab-2 | Anti-Mouse TORC1/CRTC1 monoclonal antibody | Mouse |
GM-Tg-cynog-T20017-Ab-1/ GM-Tg-cynog-T20017-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TORC1/CRTC1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T20017-Ab-1/ GM-Tg-felg-T20017-Ab-2 | Anti-Feline TORC1/CRTC1 monoclonal antibody | Feline |
GM-Tg-cang-T20017-Ab-1/ GM-Tg-cang-T20017-Ab-2 | Anti-Canine TORC1/CRTC1 monoclonal antibody | Canine |
GM-Tg-bovg-T20017-Ab-1/ GM-Tg-bovg-T20017-Ab-2 | Anti-Bovine TORC1/CRTC1 monoclonal antibody | Bovine |
GM-Tg-equg-T20017-Ab-1/ GM-Tg-equg-T20017-Ab-2 | Anti-Equine TORC1/CRTC1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T20017-Ab-1/ GM-Tg-hg-T20017-Ab-2; GM-Tg-rg-T20017-Ab-1/ GM-Tg-rg-T20017-Ab-2; GM-Tg-mg-T20017-Ab-1/ GM-Tg-mg-T20017-Ab-2; GM-Tg-cynog-T20017-Ab-1/ GM-Tg-cynog-T20017-Ab-2; GM-Tg-felg-T20017-Ab-1/ GM-Tg-felg-T20017-Ab-2; GM-Tg-cang-T20017-Ab-1/ GM-Tg-cang-T20017-Ab-2; GM-Tg-bovg-T20017-Ab-1/ GM-Tg-bovg-T20017-Ab-2; GM-Tg-equg-T20017-Ab-1/ GM-Tg-equg-T20017-Ab-2 |
Products Name | Anti-TORC1/CRTC1 monoclonal antibody |
Format | mab |
Target Name | TORC1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TORC1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CRTC1/ TORC1/ MAML2 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAAV000009 | rat Crtc1 AAV plasmid |
ORF Viral Vector | vGMAAV000009 | rat Crtc1 AAV particle |
Target information
Target ID | GM-T20017 |
Target Name | TORC1 |
Gene ID | 23373,382056,684527,720274,100684638,101095803,510465,100071052 |
Gene Symbol and Synonyms | CRTC1,Mam-2,MAML2,MECT1,mKIAA0616,TORC-1,TORC1,WAMTP1 |
Uniprot Accession | Q6UUV9,Q157S1 |
Uniprot Entry Name | CRTC1_HUMAN,CRTC1_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000105662 |
Target Classification | Pathway, Tumor-associated antigen (TAA) |
The target: TORC1, gene name: CRTC1, also named as MAML2, MECT1, Mam-2, TORC-1, TORC1, WAMTP1. Enables cAMP response element binding protein binding activity. Involved in positive regulation of transcription by RNA polymerase II. Located in cytosol; nuclear body; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.